ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1120

A Comparison of Opioid-Related Outcomes Among Commercially-Insured Osteoarthritis Patients Treated with Tramadol vs. Non-Tramadol Opioids

Stuart Silverman1, James Rice2, Alan White2, Catherine Fernan2, Michael Somma2, Craig Beck3, Rebecca Robinson4 and Patricia Schepman5, 1Cedars-Sinai Medical Center, Los Angeles, CA, 2Analysis Group, Boston, MA, 3Pfizer, London, 4Eli Lilly and Company, Indanapolis, IN, 5Pfizer, New York City, NY

Meeting: ACR Convergence 2020

Keywords: Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Osteoarthritis – Clinical Poster I

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: In 2019, the American College of Rheumatology conditionally recommended tramadol for patients with hip and knee osteoarthritis (OA). While tramadol is known to be less prone to opioid use disorders, little is known about the degree to which the magnitude of these disorders differ among patients receiving tramadol relative to other non-tramadol opioids, and also the degree to which other opioid-related outcomes are lower among those receiving tramadol. The goal of this research is to compare the clinical burden of commercially-insured patients diagnosed with OA of the hip and/or knee among patients initiated on treatment with tramadol relative to those receiving non-tramadol opioids, using a large, national database in recent years.

Methods: The Optum Healthcare Solutions, Inc. data (1/2012-3/2017) were used to identify patients >18 years old with ≥2 diagnoses of hip and/or knee OA, and ≥90 days supply of tramadol or non-tramadol opioids during the three-year period from first prescription (index date) after their first OA diagnosis. Patients were required to be continuously-enrolled during the six months before (baseline) and 36 months after (follow-up) the index date. Selected clinical outcomes including rates of opioid use disorders, opioid dependence medications, constipation, fatigue, nausea, falls, and fractures. Patients in each cohort were matched 1:1 using a propensity score model accounting for baseline characteristics that included demographics, underlying comorbid conditions, medical resource use, and direct medical costs prior to initiation of treatment.

Results: Data for 14,491 patients were analyzed: 4,048 (28%) were initiated on tramadol, and 10,443 (72%) were initiated on non-tramadol opioids. After matching, 4,048 patients in each cohort were analyzed. Tramadol patients had elevated risk of opioid use disorders (1.2% of patients with opioid use disorder diagnoses), however risk of opioid use disorders was almost 3-fold higher in the non-tramadol cohort (4.2%) (p< 0.01). Consistent with those findings, rates of methadone and buprenorphine were also elevated in the non-tramadol cohort relative to the non-tramadol cohort (1.9% vs. 0.5% (p< 0.01); 3.2% vs. 1.4% (p< 0.01) respectively). Rates of other opioid-related outcomes were also lower, although quantitatively similar among the tramadol cohort vs. non-tramadol cohort, with rates of falls of 7.9% and 9.2% (p=0.03); fractures of 15.6% and 17.9% (p< 0.01); nausea of 17.4% and 20.0% (p< 0.01); fatigue of 33.5% and 37.1% (p< 0.01); and constipation of 12.9% and 15.0% (p< 0.01), respectively. Total 3-year healthcare costs of the tramadol cohort were lower than the non-tramadol cohort ($54,122 vs. $60,303 (p< 0.01), or avg. annual costs of $18,040 vs. $20,101).

Conclusion: This study reinforces that rates of opioid use disorders among OA patients initiated on tramadol are lower than those initiated on non-tramadol opioids; other negative events commonly associated with opioid treatment are lower but quantitatively similar among patients receiving tramadol and non-tramadol opioids.


Disclosure: S. Silverman, Pfizer, 1; J. Rice, None; A. White, None; C. Fernan, None; M. Somma, None; C. Beck, Pfizer, 1, 2; R. Robinson, Eli Lilly, 1, 2; P. Schepman, Pfizer, 1, 2.

To cite this abstract in AMA style:

Silverman S, Rice J, White A, Fernan C, Somma M, Beck C, Robinson R, Schepman P. A Comparison of Opioid-Related Outcomes Among Commercially-Insured Osteoarthritis Patients Treated with Tramadol vs. Non-Tramadol Opioids [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/a-comparison-of-opioid-related-outcomes-among-commercially-insured-osteoarthritis-patients-treated-with-tramadol-vs-non-tramadol-opioids/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-comparison-of-opioid-related-outcomes-among-commercially-insured-osteoarthritis-patients-treated-with-tramadol-vs-non-tramadol-opioids/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology